Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CD44 | P16070 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9926474 | 0.79 | POLB (0.48) | POLBALDH1A1TDP1CD44CASP1 | |
| SCHEMBL3725651 | 0.77 | POLB (0.40) | POLBALDH1A1TDP1CD44CASP1 | |
| SCHEMBL13765703 | 0.77 | HPGD (0.34) | — | |
| SCHEMBL405898 | 0.75 | CD44 (0.44) | POLBALDH1A1TDP1CD44CASP1 | |
| SCHEMBL24474070 | 0.71 | TDP1 (0.36) | POLBALDH1A1TDP1CD44CASP1 | |
| SCHEMBL406843 | 0.71 | POLB (0.36) | POLBALDH1A1TDP1CD44CASP1 | |
| SCHEMBL2778015 | 0.71 | CYP3A4 (0.43) | POLBALDH1A1TDP1CD44CASP1 | |
| SCHEMBL20274760 | 0.70 | CYP1A2 (0.31) | — | |
| SCHEMBL13626927 | 0.69 | MEN1 (0.33) | — | |
| SCHEMBL30064 | 0.69 | ACHE (0.42) | POLBALDH1A1TDP1CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | POLB 4705/4885ALDH1A1 1909/4885TDP1 4213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.